The inhibitory effects of the diphosphates of 9-(2phosphonylmethoxyethyl)adenine (PMEA) and its analogues on HIV reverse transcriptase and human DNA polymerases a,~, and y have been studied. The analogues investigated are the diphosphates of 9-(2phosphonylmethoxypropyl)adenine (PMPApp), 9-(2phosphonylmethoxypropyl)-2,6-diaminopurine (PMP-DAPpp), and (2R,5R)-9-[2,5-dihydro-5-(phosphonyl methoxy)-2-furanyl]adenine (D4APpp). These four compounds are much more inhibitory to HIV reverse transcriptase when an RNA template rather than a DNA template is used. The K; values for the four compounds range from 11 to 22 nM with an RNA template. The K; values for ddCTP and AZTTP are 54 nM and 8 nM, respectively. PMEApp and its analogues show varying degrees of inhibition of the human DNA polymerases. The K; values for PMEApp, PMPApp and PMPDAPpp against DNA polymerase a are in the micromolar range, while D4APpp is a poor inhibitor of this enzyme with a K; value of 65.9 11M. The lnhlbltlon of DNA polymerase~by PMEApp, PMPApp and D4APpp is minimal, while PMPDAPpp shows higher inhibition of DNA polymerase~with a K; value of 9.71 11M. The K; values for PMEApp and D4APpp against DNA polymerase yare submicromolar, while PMPApp and PMPDAPpp are much less inhibitory to this enzyme. For comparison, ddCTP was found to be a more potent inhibitor of DNA polymerases~and y than the diphosphates of PMEA and its analogues.
Introduction 9-(2-Phosphonylmethoxyethyl)adenine, an acyclic adenosine nucleotide analogue, is active against several herpesviruses including HSV-1, HSV-2, CMV and Epstein-Barr Virus (De Clercq et et., 1986; . PMEA is also active against several retroviruses (Pauwels et el., 1988) and has shown anti-HIV activity in clinical trials (H. Jaffe, Gilead Sciences, unpublished results). Like PMEA, the related analogues PMPA, D4AP and PMPDAP also have antiviral activity in vitro and in vivo (Kim et a/., 1991; Balzarini et el., 1991 Balzarini et el., , 1993 . The mechanism of action of the antiviral activity of these compounds is believed to involve binding of the viral DNA polymerases by the diphosphate derivatives of the nucleoside phosphonates and the subsequent incorporation of the analogues into the viral DNA. AZT-induced myopathy (Dalakas et a/., 1990 ) and 2',3'-dideoxycytidine (ddC)-induced peripheral neuropathy (Dubinsky et sl., 1989) have been reported. The inhibition of DNA polymerase y by the triphosphates of AZT and ddC has been implicated. as the basis for the toxicity of these two antiviral nucleoside analogues (Arnaudo et a/., 1991; Chen and Cheng, 1989) . The inhibition of DNA polymerase y by 1-(2'-deoxy-2'-fluoro-~-D arabinofuranosyl)-5-iodouracil (FIAU) triphosphate has been suggested as the cause of FIAU toxicity (Colacino et a/., 1994) . The clinical consequences of the inhibition of DNA polymerases a and~are not known. However, the inhibition of any normal biological processes may not be desirable. Similar to other antiviral nucleoside analogues, the mechanism of cytotoxic activity of PMEA and related molecules is believed to be the inhibition of human DNA polymerases by the diphosphate metabolites. This paper reports the kinetic interactions of PMEApp, PMPApp, PMPDAPpp, and D4APpp ( Fig.1) with HIV RT and human DNA polymerases a,~and y.
Results
The diphosphates of PMEA and its analogues exhibit competitive kinetics towards the corresponding natural deoxynucleoside triphosphates. The K; values for the six inhibitors against HIV RT using activated calf thymus . 218 J. M. Cherrington et al.
R=H
X=H PMEA R=CH, X=H PMPA R=CH, X=NH 2 PMPDAP D4AP 11M . The K, value of 7004 11M for PMEApp against human DNA polymerase 13 is lower than the reported K, value of 370 11M . The K, values for AZTIP and ddCTP against DNA polymerases a and 13 are in agreement with the published values (Copeland et et., 1992 (St. Clair et el., 1987) . The K; values for the six inhibitors using RNA as a template against HIV RT increase in order as AZTIP, D4APpp, PMEApp, PMPDAPpp, PMPApp and ddCTP ( Table 1 ). The published Kj value for AZTIP against HIV RT using native HIV RNA as a template was 0.01 11M (St. Clair et el., 1987) . Fig.2 shows the Lineweaver-Burk plot for the interaction of HIV RT with PMEApp using RNA as a template, which demonstrates competitive inhibition kinetics. Similar inhibition patterns are obtained for the other three molecules against HIV RT using either RNA or DNA as a template. The K; values against DNA polymerase a in increasing order are 1.18, 3.18, 5.2, 65.9, 87.1 and 258 11M for PMEApp, PMPDAPpp, PMPApp, D4APpp, ddCTP and AZTIP, respectively. The K; values against DNA polymerase 13 in increasing order are 1. 32, 9.71, 57.6, 7004, 81 .7 and 140l1M for ddCTP, PMPDAPpp, D4APpp, PMEApp, PMPApp and AZTIP, respectively. The inhibition constant of PMEApp against human DNA polymerase a is in agreement with a reported value of 0.86
The data presented in Table 1 demonstrate The plot was generated by the KinetAsyst program (which fits the data into competitive, non-competitive and uncompelitive inhibition patterns). The data were found to have the best fit with a competitive inhibition pattern. Symbols:., 0 11M PMEApp;., 0·1 11M PMEApp; +,0·31lM
PMEApp. analogues obtained for the inhibition of HIV RT using RNA as a template are significantly lower than those obtained using DNA as a template. PMEApp and related analogues exhibit inhibitory activity as potent as that of AZTTP and ddCTP against HIV RT.
The data presented in Table 2 PMEA is currently in clinical trials for the treatment of HIV and HBV infections. The diphosphates of the other three nucleoside phosphonate analogues exhibit potent inhibitory activity against HIV-RT and have lower inhibitory activity against some of the human DNA polymerases than PMEA. Further study of these potential anti-HIV clinical candidates is therefore warranted.
Materials and Experimental Procedures: Chemistry

Nucleotides and chemicals
Radioactive deoxynucleoside triphosphates (dNTPs) were purchased from New England Nuclear, Inc. ddCTP, dNTPs, Heparin agarose hi-trap column and activated calf thymus DNA were from Pharmacia. Bovine serum albumin, dithiothreitol, KCI, MgCI 2 , glycerol and Tris-HCI were from Sigma. DE-52 cel-
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lulose was obtained from Whatman, Inc. AZT triphosphate (AZTTP) was from Moravek Biochemical (Brea, California).
Preparation of PMEApp, PMPDAPpp and PMPApp
PMEA was prepared as described . PMPA and PMPDAP were prepared as described by Yu et al., (1991) . The diphosphates of these compounds were prepared by Sierra Bioresearch, Tucson, Arizona following the published procedure (Holy et el., 1987) and analysed by ion-exchange HPLC to confirm their purity.
Preparation of D4APpp
To a solution of (2S-cis)-[[[5-(6-Amino-9H-purin-9"yl)-2,5-dihydro-2-furanyljoxyj:methyljphosphonate, disodium salt (50 mg in H 20/tert-butanol = 3 ml/3 ml; Kim et al.,1991) was added morpholine (60 mg) and dicyclohexylcarbodiimide (142 mg), and the resulting mixture was refluxed overnight. An additional 2.2 equivalents of morpholine and DCC were added, along with 1 ml of H 20 and 1 ml of ten-butanol and reflux was continued for an additional 3 h, at which point HPLC analysis indicated complete conversion. The solution was cooled, concentrated, diluted with H 20 and extracted with ether. The aqueous phase was filtered and concentrated to a brown oil. This oil was dissolved in a small volume of absolute ethanol and poured into chilled (O°C) ether. The resulting precipitate was centrifuged and the liquid was decanted. The solid was co-evaporated with absolute ethanol several times and the resulting morpholidate was directly treated with tetrabutylammonium pyrophosphate (2.4 ml of a 0.2 M solution in CH 3CN) and tributyl amine (89.0 mg) and stirred at room temperature under argon for 15 h. The reaction was judged complete by silica TLC analysis and the solution was diluted with H 20 and extracted with ether. The aqueous portion was concentrated and purified by ionexchange HPLC (Dionex PA-100 column, buffer A: 75mM LiCI/5mM LiOH; Buffer B: 1 M LiCI/5mM LiOH; gradient was 100% A to 100% B in 25 min) followed by desalting on a reverse-phase HPLC (Dynamax 300A C-18 column, buffer A: H 20; Buffer B: CH 3CN; gradient was 100% buffer A for 20 min, 100% buffer A to 90% buffer B in 5 min, then 90% buffer B). The identity and purity of the resulting D4APpp were confirmed by ion-exchange HPLC, 'H NMR and 31 P NMR analysis. 
Materials and Experimental Procedures: Biology
Enzymes
Human DNA polymerase a purified from Hela cells and recombinant human DNA polymerase pwere purchased from Molecular Biology Resources (Abbots et el., 1988; Kumar et el., 1990) . DNA polymerase ' Y was purified and characterized from A3.01 cells as described (Cherrington et al., 1994) . 1000-fold concentrated HIV-1(1IIb) (direct pelleted) was purchased from Advanced Biotechnologies (Baltimore, MD). This concentrated virus sample was disrupted by adding triton X-100 to a final concentration of 0.2% and used as the source of HIV RT. Linear initial rates were obtained with this enzyme in all of the assays.
Kinetic analysis
Kinetic constants were determined by fitting the initial rate data to Lineweaver-Burk plots using the KinetAsyst program (Think Technologies, based on the algorithms described by Cleland, 1979) .
Enzyme assays for DNA polymerases a, f3 and y Assays were carried out as previously described 1993 Starnes and Cheng (1989) , except that a defined sequence of RNA-DNA template-primer was used in place of the homopolymeric primer template. 0.0006 units of HIV RT were used per 60-1l1 reaction. The RNA-DNA template-primer used for the reverse transcriptase assays was derived as follows. The oligonucleotides 5'-GATCCTCTCTT-CTCTCTGTCAAATCCCACGTTACATGGTCAG-3' and 5'-TCG-ACTGACCATGTAACGTGGGATTTGACAGAGAGAAG-AGAG-3' were annealed and ligated into pGEM3Z that had been digested with BamHI and SaIl. The resultant recombinant plasmid was linearized with Hind"l and then transcribed with T7 RNA polymerase, generating an RNA molecule of 86 nucleotides. This RNA template was annealed to the DNA primer 5'-TGACCATGTAACGTG-3' and used as the primer template for RNA-directed DNA synthesis by HIV RT. This specifically designed template sequence allowed the incorporation of 10 molecules of dATP during the first 26 incorporations of dNTPs. The K m of this primer template was determined to be 136 nM; reactions carried out to determine Kj values of various inhibitors contained 3-fold (408 nM) the K m concentration of this template-primer.
